The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
MacdonaldJ.S., ScheinP.S., WoolleyP.V.5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med.1980; 93: 533–536.
2.
KleinH.O., WickramanayakeP.D., DieterleF.High-dose MTX/5-FU and Adriamycin for gastric cancer. Semin Oncol.1983; 10(Suppl 2): 2931.
3.
National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology: Gastric cancer, Version 1.2005. Available at: http://www.nccn.org. Accessed on September 26, 2005.
4.
KelsenD., KarpehM., SchwartzG.Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol.1996; 14: 1818–1828.
5.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–109.
6.
WilsJ., BleibergH., DalesioO.An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with Adriamycin in advanced measurable gastric cancer. J Clin Oncol.1986; 4: 1799–1803.
7.
KleinH.O., WilsJ., BleibergH.An EORTC Gastrointestinal (GI) Group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with Adriamycin (FAMTX) vs 5-fluorouracil, Adriamycin and mitomycin (FAM) in advanced gastric cancer. Med Oncol Tumor Pharmacother.1989; 6: 171–174.
8.
KleinH.O.Long-term results with FAMTX (5-fluorouracil, Adriamycin, methotrexate) in advanced gastric cancer. Anticancer Res.1989; 9: 1025–1026.
9.
WilsJ.A., KleinH.O., WagenerD.J.Sequential high-dose methotrexate and fluorouracil combined with doxorubicin—a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol.1991; 9: 827–831.
10.
MuradA.M., SantiagoF.F., PetroianuA.Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer.1993; 72: 37–41.
11.
WebbA., CunninghamD., ScarffeJ.H.Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol.1997; 15: 261–267.
12.
VanhoeferU., RougierP., WilkeH.Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol.2000; 18: 2648–2657.
13.
CocconiG., CarliniP., GamboniA.Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol.2003; 14: 1258–1263.
14.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Available at: http://www.nccn.org/. Accessed on October 1, 2005.
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol.2003; 30(Suppl 13): 10–17.
19.
OzerH., ArmitageJ.O., BennettC.L., 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18: 3558–3585.
20.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–1799.
21.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–402.
22.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22: 2918–2926.
23.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24: 969–989.
24.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
